REIA

REIA catalogs and analyzes adenosine-to-inosine (A-to-I) RNA editing sites and integrates multi-omic data to investigate their roles in human cancers.

Key Features:

• Extensive Database: Curates 8,447,588 A-to-I RNA editing sites (RESs) from 9,895 patients across 34 cancer types with primary sources including TCGA and GEO.
• Multi-Omic Integration: Integrates 13 distinct types of multi-omic data to enable cross-layer analyses of RNA editing in cancer.
• Site-specific and Quantitative Analyses: Provides site-specific querying and annotation, quantification of editing levels, and profiling of cancer-specific edits.
• Comparative and Proteogenomic Analysis: Performs comparative analyses of multi-omic features between edited and non-edited groups and identifies novel peptides, reporting 658 mass spectrometry-supported peptides not previously documented.

Scientific Applications:

• Functional Studies: Investigating the functional implications of A-to-I RNA editing in cancer development and progression.
• Multi-Omic Correlation: Correlating RNA editing status with genomic, transcriptomic, and proteomic alterations across cancer types.
• Biomarker and Peptide Discovery: Identifying mass spectrometry-supported novel peptides and potential biomarkers or therapeutic targets arising from RNA editing events.

Methodology:

Integrates A-to-I RNA editing calls curated from TCGA and GEO (8,447,588 RESs from 9,895 patients across 34 cancers) with 13 types of multi-omic data, quantifies editing levels, profiles cancer-specific edits, conducts comparative analyses between edited and non-edited groups, and identifies peptides supported by mass spectrometry.